HomeCompareCTKYY vs ABBV

CTKYY vs ABBV: Dividend Comparison 2026

CTKYY yields 7380.07% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTKYY wins by $2782548293338877.00M in total portfolio value
10 years
CTKYY
CTKYY
● Live price
7380.07%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2782548293338877.00M
Annual income
$2,710,305,372,256,298,600,000.00
Full CTKYY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CTKYY vs ABBV

📍 CTKYY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTKYYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTKYY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTKYY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTKYY
Annual income on $10K today (after 15% tax)
$627,306.27/yr
After 10yr DRIP, annual income (after tax)
$2,303,759,566,417,853,700,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CTKYY beats the other by $2,303,759,566,417,853,700,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTKYY + ABBV for your $10,000?

CTKYY: 50%ABBV: 50%
100% ABBV50/50100% CTKYY
Portfolio after 10yr
$1391274146669438.50M
Annual income
$1,355,152,686,128,149,300,000.00/yr
Blended yield
97.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CTKYY
No analyst data
Altman Z
-1.2
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTKYY buys
0
ABBV buys
0
No recent congressional trades found for CTKYY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTKYYABBV
Forward yield7380.07%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$2782548293338877.00M$102.3K
Annual income after 10y$2,710,305,372,256,298,600,000.00$24,771.77
Total dividends collected$2777712434242760.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CTKYY vs ABBV ($10,000, DRIP)

YearCTKYY PortfolioCTKYY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$748,707$738,007.38$11,550$430.00+$737.2KCTKYY
2$52,441,451$51,640,333.83$13,472$627.96+$52.43MCTKYY
3$3,436,510,436$3,380,398,083.68$15,906$926.08+$3436.49MCTKYY
4$210,704,089,989$207,027,023,822.12$19,071$1,382.55+$210704.07MCTKYY
5$12,088,563,443,530$11,863,110,067,242.08$23,302$2,095.81+$12088563.42MCTKYY
6$649,021,749,235,005$636,086,986,350,428.00$29,150$3,237.93+$649021749.21MCTKYY
7$32,611,102,400,134,300$31,916,649,128,452,844.00$37,536$5,121.41+$32611102400.10MCTKYY
8$1,533,680,270,878,520,000$1,498,786,391,310,376,200.00$50,079$8,338.38+$1533680270878.47MCTKYY
9$67,516,748,675,306,635,000$65,875,710,785,466,630,000.00$69,753$14,065.80+$67516748675306.56MCTKYY
10$2,782,548,293,338,877,000,000$2,710,305,372,256,298,600,000.00$102,337$24,771.77+$2782548293338877.00MCTKYY

CTKYY vs ABBV: Complete Analysis 2026

CTKYYStock

CooTek (Cayman) Inc. operates as a mobile internet company in the United States, the People's Republic of China, and internationally. The company offers Fengdu Novel, a mobile application that provides users with free online novels; and Fengdu Literature, a platform covering 14 major categories of male and female preferred content, including genres of romance, fantasy, science fiction, history, and others. It also provides casual games, such as dress-up games, including Catwalk Beauty, Truth Runner, and Love Fantasy; simulation games comprising Farm Hero and Idle Land King Tycoon; puzzle games, such as Hi Hamster; and educational games consisting of Puzzle No. 1 and Idiom Hero. In addition, the company offers TouchPal Smart Input, an input method for mobile devices that supports approximately 110 languages and available on both Android and iOS operating systems. It distributes its products and acquires users primarily through user downloads from digital distribution platforms and social media. The company was founded in 2008 and is headquartered in Shanghai, the People's Republic of China.

Full CTKYY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CTKYY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTKYY vs SCHDCTKYY vs JEPICTKYY vs OCTKYY vs KOCTKYY vs MAINCTKYY vs JNJCTKYY vs MRKCTKYY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.